Використання анти-VEGF препаратів в лікуванні вторинної неоваскулярної глаукоми

Abstract

Secondary neovascular glaucoma (SNG) - the most severe form of glaucoma process. Its occurrence is associated with ischemia of the inner layers of the retina, resulting in the underlying cause, and accompanied rubeosis iris and anterior chamber angle. Vascular endothelial growth factor (VEGF) plays a signi fi cant role in the formation of newly formed blood vessels. Intravitreal administration of inhibitors of vascular endothelial growth factor - bevacizumab, pehaptanib, ranibizumab - should lead to a signi fi cant regression fi brovascular membranes. The aim of this study was to clarify the possibility of using and biological effect inhibitors VEGF pehaptaniba in the treatment of secondary neovascular glaucoma. 11 patients was observed with SNG on a background of proliferative diabetic retinopathy. Visual acuity ranged from 0.7 to 0.01. 1 dose «Macugen» (Pegaptanibum) contains 3.47 mg / ml. When we inject intravitreal pegaptanib, we observed desolation of the newly vessels in the anterior chamber angle, which nearly became invisible. Decreased the severity of macular edema in the affected area and the patient is usually immediately felt better view. In 83% of cases observed objective improvement of visual function after 2 weeks of treatment, and in 32% of patients, visual acuity increased by an average of 0,3±0,02. Intraocular pressure decreased slightly and unreliable, but appeared ability to compensate it by using antihypertensive drug . In 17% of patients with long course of the primary disease and symptomatic SNG with regular (every 6 weeks intravitreal administration) advancing stabilization of pathology and visual functions for observation for 1 year.